Saturday, October 3, 2026

Silver Price Analysis: XAG/USD Keeps Bounce Off 100-DMA Above $24.00 To Favor Bulls: (SI) Is 7% Up In The Last 10 Sessions

Via News Just in

August 28, 2023

Silver Price Analysis: XAG/USD Keeps Bounce Off 100-DMA Above $24.00 To Favor Bulls: (SI) Is 7% Up In The Last 10 Sessions
(VIANEWS) - Silver Price (XAG/USD) picks up bids to $24.30 as it defends the previous day's rebound from the 100-DMA amid the early hours of Monday's Asian trading session. FXStreet reported that in addition to the XAG/USD's U-turn from the 100-DMA, the bullish MACD signals and firmer RSI (14), not overbought, also underpin bullish bias about the bright metal. However, a horizontal area comprising multiple levels marked since January 2023, close to $24.50, appears a tough nut to crack for the Silver buyers. Silver (SI) has been up by 7.88% for the last 10 sessions. At 08:51 EST on Monday, 28 August, Silver (SI) is $24.22.

Silver price analysis: xag/usd keeps bounce off 100-dma above $24.00 to favor bulls

Overall, the Silver price remains on the buyer's radar even if the upside road remains long and bumpy., However, a horizontal area comprising multiple levels marked since January 2023, close to $24.50, appears a tough nut to crack for the Silver buyers.

Volume

Today's last reported volume for Silver is 10866, 99.99% below its average volume of 12152352817.03.

Volatility

Silver's last week, last month's, and last quarter's current intraday variation average was 1.16%, 0.28%, and 1.17%, respectively. Silver's highest amplitude of average volatility was 1.53% (last week), 1.01% (last month), and 1.17% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Silver's commodity is considered to be oversold (<=20). More news about Silver (SI).
Via News Just in

Breaking news and real-time updates on financial markets, business developments, and economic events from Via News.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com